CAPR

Business Context and Reporting Period

Company: Capricor Therapeutics, Inc. (Nasdaq: CAPR)
Filing Type: Form 10-K (Annual Report)
Reporting Period: Fiscal year ended December 31, 2024
Business Overview: Capricor is a clinical-stage biotechnology company developing cell and exosome-based therapeutics. Its lead product candidate, deramiocel, is a cell therapy for Duchenne muscular dystrophy (DMD). The company also maintains an exosome platform (StealthX™) for vaccine and therapeutic development, including a candidate for SARS-CoV-2.

Key Financial Metrics

Note: The company has no commercial product sales. Revenue is derived from collaboration and distribution agreements.

Material Changes vs. Prior Period

• Revenue Decline: Revenue decreased by approximately 12% to $22.3 million. This reflects the recognition of milestone payments from Nippon Shinyaku. In 2024, the company recognized $10.0 million upon the submission of the Biologics License Application (BLA) for deramiocel, whereas 2023 revenue included the recognition of the first $10.0 million milestone and ratable recognition of the upfront payment.
• Increased Operating Loss: Net loss widened to $40.5 million (from $22.3 million) primarily due to a 37% increase in R&D expenses. This increase was driven by the HOPE-3 Phase 3 clinical trial, the HOPE-2 Open Label Extension (OLE), and expanded manufacturing efforts.
• Liquidity Improvement: Cash and marketable securities increased significantly from $39.5 million to $151.5 million. This was fueled by net proceeds of approximately $152.3 million from equity financings in 2024, including an underwritten public offering ($86.3 million), a private placement ($15.0 million), and an at-the-market offering ($58.4 million).

Guidance, Outlook, and Management Commentary

• Regulatory Milestone: In December 2024, Capricor submitted a BLA for deramiocel to treat DMD cardiomyopathy. The FDA accepted the application for review and granted Priority Review with a Prescription Drug User Fee Act (PDUFA) target action date of August 31, 2025.
• Clinical Progress: The Phase 3 HOPE-3 trial is ongoing with approximately 105 subjects enrolled. A futility analysis for Cohort A was positive in late 2023. The HOPE-2 OLE study continues to show improvements in cardiac function and upper limb performance.
• Exosome Platform: The company submitted an Investigational New Drug (IND) application for its StealthX™ vaccine (SARS-CoV-2) to the FDA. A Phase 1 clinical study is planned to be conducted by the National Institute of Allergy and Infectious Diseases (NIAID) subject to regulatory approval, with a target initiation in the second quarter of 2025.
• Strategic Partnerships: Capricor has exclusive distribution agreements with Nippon Shinyaku for the U.S. and Japan. A binding term sheet for European distribution was signed in September 2024, with negotiations for a definitive agreement extended to April 30, 2025. Potential milestones under these agreements total over $1.4 billion.
• Liquidity Outlook: Management estimates current cash resources are sufficient to fund operations into 2027.

Investor Verification Checklist

• BLA Acceptance & PDUFA Date: Verify the FDA's official acceptance of the deramiocel BLA and the confirmed PDUFA date of August 31, 2025.
• HOPE-3 Trial Status: Confirm enrollment numbers and any interim data releases for the Phase 3 HOPE-3 trial, which is critical for potential label expansion beyond cardiomyopathy.
• Manufacturing Capacity: Assess the readiness of the San Diego facility for commercial-scale manufacturing and FDA inspection status, as this is a prerequisite for launch.
• European Term Sheet: Monitor the finalization of the definitive agreement with Nippon Shinyaku for European rights, including the potential $20.0 million upfront payment.
• Exosome IND Approval: Track the FDA's decision on the StealthX™ vaccine IND and the timeline for the NIAID Phase 1 study initiation.
• Cash Burn Rate: Review quarterly cash flow statements to ensure the burn rate aligns with the "into 2027" liquidity runway estimate.